Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > New Preclinical Data
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(21)
•••
Comment by BottomBrokeron Mar 30, 2023 9:12am
58 Views
Post# 35368769

RE:RE:New Preclinical Data

RE:RE:New Preclinical Data
M101 wrote:
bball67 wrote: So, Promis put out a press release on March 13th saying they will present new preclinical data as part of their presentation in Europe and it would be available on the Promis website on March 28. So, I don't know why the headline of the press release would tout new preclinical data if it wasn't something important or significant. I hope it is not a dud. 

Anyone here figure out what if any new preclinical data is worked into the poster?

Because if not then I must invoke the famous (and last) mocking words of Cool Hand Luke: "What we have here is a failure to communicate" 



Seemed like more of the same to me. Don't get me wrong, less brain bleeding/fewer side effects are  definitely a reason for optimism, but I think we already knew that. Right?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities